Resilience, a technology-driven biomanufacturing company focused on broadening access to complex medicines, announced it has secured long-term debt financing of up to $825 million from Oak Hill Advisors (OHA). The funding would strengthen the company’s balance sheet and accelerate its contract development and manufacturing organization (CDMO) strategy, particularly across its operations in Cincinnati and Toronto.
The new capital will enable Resilience to expand its manufacturing network and further develop its position as a leading CDMO specializing in sterile drug production. The company’s Cincinnati facility is undergoing significant expansion and is expected to become one of the largest and most advanced sterile injectable, device assembly, and packaging operations in North America.
OHA, a global investment firm with over three decades of experience and a history of supporting growth in the life sciences sector, is providing a $600 million first-lien commitment as part of the financing. An initial tranche of $525 million is anticipated to close later in the fourth quarter, with the remaining capital to be deployed in subsequent years as needed. The financing is subject to customary closing conditions.
The investment is expected to enhance Resilience’s ability to deliver advanced biomanufacturing services at scale, addressing growing demand for cell-based and biologic therapies. Alongside the new financing, Resilience has also resolved lease obligations related to underutilized sites, further strengthening its financial position and operational efficiency.
Resilience continues to build a North American network of high-performance biomanufacturing facilities, offering end-to-end capabilities spanning biologics, cell-based therapies, and aseptic drug production. The company partners with leading biopharma innovators to bring complex therapies to market more efficiently and reliably.
Advisor/counsel: Jefferies acted as financial advisor, and Kirkland & Ellis served as legal counsel to Resilience in connection with the transaction.
KEY QUOTES:
“This financing is a pivotal step forward for our enterprise and positions us well to advance our ongoing transformation efforts backed by favorable industry tailwinds in the CDMO sector. This new capital will support the continued buildout of our core manufacturing operations and enable us to serve our customers with stability and excellence into the future, particularly at a time when pharmaceutical onshoring is a national priority. Partnering with OHA and our supportive long-time shareholders, we are confident that Resilience now has the right focus, footprint and financial profile to capitalize on the exciting strategic growth opportunities ahead.”
William S. Marth, President and Chief Executive Officer, Resilience
“We believe Resilience is uniquely positioned to scale its advanced manufacturing capabilities and meet the increasing demand for complex medicines. Our investment reflects conviction in the company’s leadership team, strategic positioning and ability to generate long-term value in a sector undergoing rapid transformation. We look forward to supporting Resilience as it expands its footprint and strengthens its role in the global biomanufacturing ecosystem.”
Joe Goldschmid, Managing Director, Oak Hill Advisors
